Coya Therapeutics (COYA) Change in Account Payables (2022 - 2026)
Coya Therapeutics (COYA) reported Change in Account Payables of -$154713.0 for Q1 2026, down 251.86% on a YoY basis from $101879.0 in Q1 2025, and down 205.88% sequentially from -$50580.0 in Q4 2025.
Coya Therapeutics (COYA) Change in Account Payables (2022 - 2026) Analysis & Trends
Coya Therapeutics (COYA) has 5 years of Change in Account Payables data on file, last reported at -$154713.0 in Q1 2026.
- For the quarter ending Q1 2026, Change in Account Payables fell 251.86% year-over-year to -$154713.0; the trailing twelve-month figure through Mar 2026 stood at -$783598.0 (down 867.75% YoY), and the FY2025 full-year result was -$527006.0, down 210.38% from the prior year.
- Change in Account Payables declined to -$154713.0 in Q1 2026, from -$50580.0 in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $1.3 million in Q4 2024 to a low of -$1.5 million in Q3 2024.
- A 5-year average of $55284.2 and a median of $101879.0 in 2025 frame the typical range for Change in Account Payables.
- Across the five-year window, Change in Account Payables soared 654.03% in 2023 and sank 475.92% in 2024, its largest moves.
- Tracing COYA's Change in Account Payables over 5 years: stood at $389106.0 in 2022, then advanced by 22.52% to $476727.0 in 2023, then surged by 162.5% to $1.3 million in 2024, then tumbled by 104.04% to -$50580.0 in 2025, then plunged by 205.88% to -$154713.0 in 2026.
- Business Quant data shows COYA's Change in Account Payables at -$154713.0 in Q1 2026, -$50580.0 in Q4 2025, and $180358.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Nanobiotix | 1,785.82 Bn | 1,785.76 Bn | - | - |
| 2 | Akari Therapeutics | 979.03 Bn | 979.03 Bn | - | - |
| 3 | BeOne Medicines | 472.86 Bn | 468.07 Bn | 1.35 Bn | -42.19 Mn |
| 4 | Vertex Pharmaceuticals | 123.71 Bn | 116.47 Bn | 2.59 Bn | 35.60 Mn |
| 5 | Regeneron Pharmaceuticals | 71.61 Bn | 62.86 Bn | 3.31 Bn | - |
| 6 | Belite Bio | 62.00 Bn | 62.00 Bn | - | - |
| 7 | Argenx Se | 54.62 Bn | 49.44 Bn | 1.41 Bn | - |
| 8 | Alnylam Pharmaceuticals | 38.09 Bn | 35.08 Bn | 959.66 Mn | - |
| 9 | Revolution Medicines | 36.08 Bn | 36.08 Bn | - | 16.86 Mn |
| 10 | Coya Therapeutics | 91.26 Mn | 40.53 Mn | - | -154,713.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -154,713.00 |
| Mar 31, 2026 | -154,713.00 |
| Dec 31, 2025 | -50,580.00 |
| Dec 31, 2025 | -50,580.00 |
| Sep 30, 2025 | 180,358.00 |
| Sep 30, 2025 | 180,358.00 |
| Jun 30, 2025 | -758,663.00 |
| Jun 30, 2025 | -758,663.00 |
| Mar 31, 2025 | 101,879.00 |
| Mar 31, 2025 | 101,879.00 |
| Dec 31, 2024 | 1.25 Mn |
| Dec 31, 2024 | 1.25 Mn |
| Sep 30, 2024 | -1.49 Mn |
| Sep 30, 2024 | -1.49 Mn |
| Jun 30, 2024 | 238,802.00 |
| Jun 30, 2024 | 238,802.00 |
| Mar 31, 2024 | 477,265.00 |
| Mar 31, 2024 | 477,265.00 |
| Dec 31, 2023 | 476,727.00 |
| Dec 31, 2023 | 476,727.00 |